# **Tafenoquine For Malaria Elimination?**

#### Prof G Dennis Shanks Director ADF Malaria and Infectious Disease Institute COL US Army (retired)

Identification of specific products are not to be considered a commercial endorsement The opinions expressed are those of the author and are not necessarily those of the ADF

## Are We Wining the War Against Malaria?

- Gains in morbidity mortality reduction in Melanesia from rapid diagnostic tests, artemisinin combination therapy and insecticide treated bed nets
- This progress is fragile and there is evidence of negative developments when external resources are limited



# **Cycle of Malaria Control Followed by Epidemics**

- Malaria control requires consistency; malaria elimination requires perfection
- Melanesian countries have gone through cycles of control / failure when cases drop to point that donors are no longer interested
- Vivax is now a large proportion of malaria cases in Solomon Islands



#### Not Much Malaria in SE Asia, but It Is Ugly

- Falciparum malaria left in small pockets of highly drug resistant parasites
- Residual transmission in SE Asia is not found in the usual tourist destinations
- Rural areas of Cambodia and Myanmar are problematic



#### Low Risk Is Not the Same as No Risk

- What level of risk is tolerable?
- When do drug adverse events become greater than disease risk?
- Very hard to get malaria in Latin America, SE Asia, India if you are not living like a local (visiting friends and relatives)



## **Algorithm for Malaria Elimination in Melanesia**

- Relapsing malaria (vivax) will be much harder to eliminate than falciparum
- Drugs that cure relapsing malaria are required
- Use of primaquine (and now tafenoquine) is not optional if we intend to eliminate malaria



#### **China Eliminated Vivax Malaria with Primaquine**

- Mass campaigns of 1970-90s distributed >100M primaquine in areas with epidemic vivax
- Surveillance with focal MDA then used to finish remaining areas of transmission
- Estimated severe adverse events (hemolysis) at 1:10,000 despite no G6PD screening



#### Tafenoquine: A 'New' 8-aminoquinoline

- Tafenoquine (TQ) is a long-acting (T ½ 14 days) primaquine analogue
- TQ kills all stages of parasite including liver but is relatively slow acting against blood parasites
- Approved by US FDA and Australian TGA for both single dose treatment and weekly malaria chemoprophylaxis in G6PD tested



## Long History of Tafenoquine

- First synthesized in 1978
- First in humans at WRAIR, Washington DC in 1996
- Phase 2 chemoprophylaxis field trial in Kenya 1998
- Phase 3 chemoprophylaxis trial Australian Army 2000-01
- Phase 2 relapsing malaria treatment multi-center 2010-12
- Phase 3 relapsing malaria treatment multi-center 2013-16

# **Tafenoquine: Long-Acting Primaquine-Like Drug**

- Weekly dosing likely to partially fix compliance problems
- Has same G6PD liability as primaquine so need to have measured G6PD status once
- Other wise well tolerated and most appropriate for very high risk travellers



#### **Killing Residual Hepatic Parasites (Hypnozoites)**

- Quiescent post-sporozoite parasite in hepatocyte able to reactivate months after infection
- 8-aminoquinolines only class of drug known to kill hypnozoites; primaquine only drug currently available for clinical use

 Destruction of hypnozoites necessary for malaria elimination



#### **Getting Around Genetic Polymorphisms?**

- G6PD: Extremely common (10%) in some male populations in malaria endemic areas; difficult to evaluate females
- Rapid tests G6PD becoming available but add greatly to cost
- Cytochrome P450 metabolism: 2D6 null individuals do not clear hypnozoites with primaquine



Translational Research 2015 Jun;165(6):677-88

#### **Problems with G6PD Testing in Australia**

- Males are easy as G6PD measurements are unambiguous for X linked gene
- Female heterozygotes may test normal but still be liable to hemolysis in half their erythrocytes
- Currently one does not get a quantative G6PD value



# **Tafenoquine Chemoprophylaxis in East Timor**

- Soldiers received either weekly tafenoquine 200 mg (n=492) or mefloquine 250 mg (n=162) for 6 months
- No failures during prophylaxis followed by late vivax relapses 16-20 weeks later in 4 TQ and 1 MQ despite PQ 30mg x14
- Treatment related adverse events were 13.4 % TQ and 11.7 % MQ; vortex keratopathy noted in >90% of TQ which spontaneously resolved over 1 year



# **Tafenoquine Eradication after East Timor**

- >400 malaria episodes during East Timor intervention from 1999-2004 most of them late vivax relapses while in Australia
- Australian soldiers received TQ (n=636) 200mg x3 as eradication therapy vs. PQ (n=289) with 4.9% vs. 10% relapses median 106 d (68-332) after return to Australia
- Most frequent adverse events for single course of TQ (600mg) were GI similar to that seen with primaquine



Figure. Kaplan-Meier survival curve of time from baseline to parasitaemia with vivax malaria in Australian Defence Force personnel receiving primaquine (solid line) or tafenoquine (broken line) post-exposure malaria prophylaxis, November 1998-September 1999.

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2002) 96, 683-684

#### **Should We Worry About the Eye Findings with TQ?**

- Phospholipidosis was a known risk from animal toxicology
- All corneal findings were asymptomatic and spontaneously resolved
- Currently being tested out to 12 months continuous weekly use



## **Directions to Use Prophylactic Tafenoquine**

- Loading regimen of 200mg x3 OD followed by 200mg weekly for adults
- Best taken with food for improved absorption
- Working on pediatric formulation / indication



#### Large Doses Tafenoquine Protect for 10 Weeks

- Loading dose of 1200 mg TQ given during field trials in Kenya
- Loading dose remained as effective as weekly medication out to 10 weeks post drug (about 7 half lives)
- Likely that doses < 200 mg still have good antimalarial effect lasting at least 2 weeks



#### **Possible Tafenoquine Scenario for Elimination?**

- Pulse of drug into a defined area to stop transmission
- Mass drug administration in order to eliminate relapses
- Stopping an on-going epidemic with tafenoquine



### **Other Aspects of Tafenoquine Being Tested**

- Extend from 6m to 12m for prevention
- Monthly dosing regimens or single dose short-term protection
- Presumptive treatment (post travel eradication)

![](_page_19_Picture_4.jpeg)

## **Public Health Indications for Tafenoquine?**

- Tafenoquine kills gametocytes thus blocking transmission
- Destroy the hypnozoite reservoir to stop source of relapsing malaria
- Unlikely to be used for mass drug administration until G6PD problem is better worked out

![](_page_20_Picture_4.jpeg)

#### **Conclusions for Traveller's Malaria**

- Most important function of travel medicine practitioner is to accurately evaluate risk
- Menu of chemoprophylaxis choices now includes a safe weekly drug: tafenoquine
- Still are good reasons to use atovaquone / proguanil or doxycycline in some travellers

![](_page_21_Picture_4.jpeg)

![](_page_22_Picture_0.jpeg)

# Acknowledgements

BILL & MELINDA GATES franderien

![](_page_22_Picture_3.jpeg)

Queensland Institute of Medical Research

#### **Bill and Melinda Gates Foundation, Seattle USA**

**QIMR-Berghofer, Brisbane, Queensland, Australia** 

University of Queensland, School of Public Health, Herston, QLD

Walter Reed Army Institute of Research, Washington DC

**World Health Organization** 

![](_page_22_Picture_10.jpeg)

![](_page_22_Picture_11.jpeg)

![](_page_22_Picture_12.jpeg)

![](_page_22_Picture_13.jpeg)